74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Omnicell Inc
Closed
SectorHealthcare
31.11 1.4
Overview
Share price change
24h
Min
30.13
Max
31.26
Income | 7.2M 16M |
|---|---|
Sales | 25M 307M |
P/E Sector Avg | 109.815 57.333 |
EPS | 0.6 |
Profit margin | 5.162 |
Employees | 3,670 |
EBITDA | -15M 12M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +55.72% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | -647M 1.4B |
|---|---|
Previous open | 29.71 |
Previous close | 31.11 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Omnicell Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Omnicell Inc Forecast
Price Target
By TipRanks
55.72% upside
12 Months Forecast
Average 48.6 USD 55.72%
High 69 USD
Low 36 USD
Based on 7 Wall Street analysts offering 12 month price targets forOmnicell Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
